Total: $59.1 million

Top drug
Advair (COPD): $47.7 million
Watch the TV commercial here >>

GlaxoSmithKline ($GSK) put its advertising dollars to work generating sales of asthma treatment Advair. It was its top-selling drug at $7.7 billion last year, making up about 20% of the company's sales. The respiratory drug actually went off patent in 2010, but its Diskus inhaler is so difficult to copy that no generics have challenged it and none are on the horizon. That is despite an FDA decision to limit the clinical testing required for approval. Teva Pharmaceutical Industries ($TEVA), the largest generic drugmaker in the world, said that even with the new ground rules, it doesn't expect to see true substitutes for the GSK best-seller before 2018. U.S. sales of Advair in the first 6 months of the year were up 5% to $3.6 billion.


Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.